On Demand 2017 Obstructive Lung Disease (MOC)
Price: $25 members, $35 non-members
You can earn up to 1.25 AMA PRA Category 1 Credits™, and up to 1.25 MOC Part II Self-Assessment credits.
This session examines the evidence for treatment of obstructive lung disease.
- GINA 2017: How Will This Change My Practice?
- GOLD 2017: How Will This Change My Practice?
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 1.25 credits as meeting the requirements for MOC Part II Self-Assessment.
Medical professionals who treat patients with allergic and/or immunological conditions:
- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Nurses and advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals
Upon completion of this session, participants should be able to:
- Evaluate the potential positive outcomes from GINA add-on therapy.
- Choose the patient population that will not have sufficient burden of disease to necessitate GOLD therapy.
- Evaluate all of the evidence to provide guidance for appropriate cost-effective use of these medications.
- Michasel Wechsler, MD
- Paul O'Byrne, MD
- Peter Barnes, MD
- Jeffrey Drazen, MD
- 1.25 AMA PRA Category 1 Credit™
- 1.25 Attendance
- 1.25 MOC